Sustainability

Cellectis is pivoting from allogeneic CAR-T development to become an in vivo gene editing company, discontinuing its lasme-cel and eti-cel programs.

Novo Nordisk rebrands as "Novo" under it's "Lasting health starts now" tagline, pairing both with a new cultural framework called "The Novo Way."

The advantages of synthetic advisory boards in stress-testing hypotheses and iterating across a greater scope of scenarios than live boards allow.

Sebastian Arana, head of process solutions at MilliporeSigma, discusses the operational tradeoffs facilities face as they move toward multi-modality production and the persistent cost and scale-up challenges shaping cell and gene therapy, mRNA, and ADC manufacturing.

Nate Hill, co-founder & CEO, Strive Pharmacy, breaks down looming questions around the completed FDA PCAC hearing on peptides.

Novartis suspends eight autoimmune trials of its CAR-T therapy Rap-cel after three cases of fatal outcomes, while Bristol Myers Squibb voluntarily pauses enrollment in its Zola-cel autoimmune studies over transient inflammatory events.

Rohit Tripathi, VP of Industry Strategy at RELEX, talks with Pharmaceutical Executive about the impact new phased tariffs will have on reshoring pharma manufacturing.

LEO Pharma agrees to acquire dersimelagon, OmniAb signs a ion channel discovery collaboration with Eli Lilly, Chugai grants GSK an exclusive worldwide license to AID351, and BioMarin acquires Alesta Therapeutics to gain ALE1.

Silence Therapeutics and AbCellera launched respective common share public offerings, and Beyang Therapeutics and Remepy closed $30+ million oversubscribed Series A rounds.

Renewal of FDA's Priority Review Voucher program is driving a rebound in U.S. rare disease biotech investment, while the UK continues to lag.

Jazz Pharmaceuticals agrees to acquire Actio Biosciences for $820 million upfront plus up to $500 million in milestones for ABS-1230.

Gerren McHam, vice president of Government and External Affairs, API Innovation Center, discusses what is compounding U.S. pharmaceutical supply chain vulnerabilities.

AstraZeneca's Wainua failed to meet the primary endpoint of a late-stage trial in transthyretin-mediated amyloid cardiomyopathy, sending shares down nearly 10% in their largest single-day decline since late 2024.

The looming patent cliff exposes a deeper industry challenge, as biopharma companies face up to $400 billion in at-risk revenue while struggling to translate abundant data into actionable insight needed to compete in increasingly crowded markets.

BioNTech reports its first quarter finical results, including losses and declining Covid-19 revenue as the company accelerates its oncology investments and restructures its manufacturing footprint.

Jeff Golfman, founder and president of Send 123, in a conversation with Pharmaceutical Executive, discusses how rising geopolitical tensions around Iran and broader global disruptions are reshaping pharmaceutical and medical supply chains.

UnitedHealth Group reported stronger-than-expected first-quarter earnings and raised its full-year outlook, signaling improving cost control and early progress in stabilizing performance.

Morten Graugaard, CEO, Orbis Medicines, discusses the importance of oral biologics and the industry impacts of FDA's approval of Icotyde.

Disruptions from the U.S.and Iran conflict moves across key transit routes and threatens the flow of active ingredients, price spikes, and heightened risk of drug shortages worldwide.

Pfizer and BioNTech halted a large U.S. clinical trial targeting healthy adults aged 50 to 64 after enrollment shortfalls made it impossible to generate the post-marketing data the FDA required.

The deal adds OM336, a BCMAxCD3 bispecific T cell engager showing early efficacy in rare antibody-mediated autoimmune diseases, to Gilead's pipeline.

Novo Nordisk posted strong 2025 sales growth driven by obesity treatments and U.S. market performance, but tempered operating profits signal a more cautious outlook for 2026.

Novartis reported solid full-year growth and margin expansion in 2025, but also set the stage for a challenging year ahead marked by major patent expirations.

The company composed a letter addressed to global governments to harness competitiveness and innovation to navigate the current global trade economy.

Johnson & Johnson reached a voluntary agreement with the U.S. government to enhance patient access, lower drug costs, and expand domestic manufacturing.